Alpha Tau Initiates European Trial for Pancreatic Cancer Therapy

Event summary

  • Alpha Tau Medical initiated the ACAPELLA clinical trial in Europe, evaluating Alpha DaRT combined with capecitabine for inoperable pancreatic cancer patients.
  • The trial is enrolling up to 40 patients and is being conducted across multiple centers in France, with the first patient treated at CHU Grenoble Alpes on April 23, 2026.
  • ACAPELLA targets patients who have completed first-line mFOLFIRINOX chemotherapy and have no standard consolidation therapy options.
  • The trial’s primary endpoint is the incidence of device-related serious adverse events, with secondary endpoints including tumor response and overall survival.

The big picture

Alpha Tau's ACAPELLA trial addresses a significant unmet need in pancreatic cancer treatment, a market with approximately 140,000 new cases annually in Europe. The trial’s focus on patients who have exhausted standard chemotherapy regimens highlights the potential for Alpha DaRT to fill a critical gap in the treatment landscape. The simultaneous advancement of both the ACAPELLA and IMPACT trials positions Alpha Tau to build a robust clinical evidence base for its Alpha DaRT technology, but also increases the pressure to deliver positive results.

What we're watching

Clinical Efficacy
The trial’s ability to demonstrate a meaningful improvement in survival or tumor response will be critical for Alpha Tau’s commercial prospects, given the lack of standard treatment options for this patient population.
Regulatory Pathway
European regulatory approval will depend on the ACAPELLA trial’s results and could be influenced by the ongoing IMPACT trial in the United States, creating a potential for accelerated or divergent pathways.
Market Adoption
The successful integration of Alpha DaRT into existing endoscopic ultrasound workflows and acceptance by European GI oncologists will determine the therapy’s ultimate market penetration.

Related topics

Pharmaceuticals